Compare HIMS & ARWR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | HIMS | ARWR |
|---|---|---|
| Founded | 2017 | 2003 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medical/Nursing Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 8.9B | 9.6B |
| IPO Year | N/A | 1993 |
| Metric | HIMS | ARWR |
|---|---|---|
| Price | $35.06 | $68.99 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 12 | 10 |
| Target Price | $44.90 | ★ $63.70 |
| AVG Volume (30 Days) | ★ 13.9M | 3.3M |
| Earning Date | 11-03-2025 | 02-09-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 20.76 | N/A |
| EPS | ★ 0.54 | N/A |
| Revenue | ★ $2,210,958,000.00 | $829,448,000.00 |
| Revenue This Year | $62.21 | N/A |
| Revenue Next Year | $18.79 | N/A |
| P/E Ratio | $66.24 | ★ N/A |
| Revenue Growth | 78.02 | ★ 23258.15 |
| 52 Week Low | $23.97 | $9.57 |
| 52 Week High | $72.98 | $72.36 |
| Indicator | HIMS | ARWR |
|---|---|---|
| Relative Strength Index (RSI) | 39.33 | 69.13 |
| Support Level | $34.31 | $59.51 |
| Resistance Level | $37.61 | $72.36 |
| Average True Range (ATR) | 1.82 | 4.32 |
| MACD | 0.03 | -0.44 |
| Stochastic Oscillator | 11.23 | 75.46 |
Hims & Hers, launched in 2017, is a telehealth platform that connects patients and healthcare providers to offer treatment options for specialties like erectile dysfunction, hair loss, skin care, mental health, and weight loss. Its offerings include generic, branded, and compounded prescription drugs as well as over-the-counter medicines, cosmetics, and supplements. The platform, which has more than 2 million subscribers, is available in all 50 states and certain European markets like the UK. It includes provider networks, electronic medical records, cloud pharmacy fulfillment, and personalization capabilities. Hims does not take insurance and only accepts payments directly from customers.
Arrowhead Pharmaceuticals Inc is an American biotechnology company. Its main target is the development of medicine to treat diseases with a genetic origin, characterized by the overproduction of one or more proteins. Its medical solutions are aimed at the genes that trigger the diseases. Its portfolio includes drugs targeting cardiovascular, Cardiometabolic, Central Nervous System, Pulmonary, Liver, Muscular, and Complement Mediated Disease. It majority products are liver disease curable.